Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
48
ROIV Quote, Financials, Valuation and Earnings
Last price:
$28.34
Seasonality move
:
8.36%
Day range:
$26.62 - $28.55
52-week range:
$8.73 - $30.33
Dividend yield:
0%
P/E ratio:
1.91x
P/S ratio:
1,471.52x
P/B ratio:
4.75x
Volume:
5M
Avg. volume:
5.8M
1-year change:
181.05%
Market cap:
$20.6B
Revenue:
$29.1M
EPS (TTM):
-$1.17
Analysts' Opinion
-
Consensus RatingRoivant Sciences Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $33.25, Roivant Sciences Ltd. has an estimated upside of 17.37% from its current price of $28.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $22.00 representing -- downside risk from its current price of $28.33.
Fair Value
-
According to the consensus of 11 analysts, Roivant Sciences Ltd. has 17.37% upside to fair value with a price target of $33.25 per share.
ROIV vs. S&P 500
-
Over the past 5 trading days, Roivant Sciences Ltd. has underperformed the S&P 500 by -3.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Roivant Sciences Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Roivant Sciences Ltd. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Roivant Sciences Ltd. reported revenues of $2M.
Earnings Growth
-
Roivant Sciences Ltd. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Roivant Sciences Ltd. reported earnings per share of -$0.38.
Enterprise value:
16.6B
EV / Invested capital:
--
Price / LTM sales:
1,471.52x
EV / EBIT:
0.75x
EV / Revenue:
1,243.96x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-21.59x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
0.74x
Gross Profit (TTM):
$8M
Return On Assets:
-18.95%
Net Income Margin (TTM):
-7558.42%
Return On Equity:
-19.87%
Return On Invested Capital:
-19.48%
Operating Margin:
-16966.13%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $68.2M | $30.5M | $13.3M | $9M | $2M | |
| Gross Profit | $46.6M | $20.7M | $8M | $6.8M | $608K | |
| Operating Income | -$919M | -$1B | -$1.2B | -$274.4M | -$339.2M | |
| EBITDA | -$903.2M | -$1B | -$1.2B | -$272.4M | -$338.5M | |
| Diluted EPS | $5.21 | -$0.14 | -$1.17 | $0.23 | -$0.38 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.3B | $1.6B | $6.8B | $5.4B | $4.7B | |
| Total Assets | $2.8B | $2.2B | $7.3B | $5.8B | $5.2B | |
| Current Liabilities | $160.7M | $244.3M | $244.9M | $141.5M | $152M | |
| Total Liabilities | $529.6M | $775.8M | $728.1M | $256.4M | $251.1M | |
| Total Equity | $2.3B | $1.4B | $6.6B | $5.5B | $5B | |
| Total Debt | $266.1M | $467.8M | $496.1M | $90.5M | $98.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$835.9M | -$775.3M | -$759.1M | -$207.3M | -$196.5M | |
| Cash From Investing | $5.3B | -$2.8B | $257.6M | $454.1M | $148.7M | |
| Cash From Financing | $662.3M | -$1.1B | -$13.4M | -$273M | $288.9M | |
| Free Cash Flow | -$838.6M | -$779.5M | -$766.9M | -$209.1M | -$191.5M | |
ROIV
Sector
Market Cap
$20.6B
$23.9M
Price % of 52-Week High
--
47.44%
Dividend Yield
0%
0%
Shareholder Yield
-0.29%
-1.9%
1-Year Price Total Return
181.05%
-18.29%
Beta (5-Year)
--
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$27.30
200-day SMA
Buy
Level
$18.90
Bollinger Bands (100)
Buy
Level
20.88 - 27.28
Chaikin Money Flow
Buy
Level
173M
20-day SMA
Buy
Level
$28.02
Relative Strength Index (RSI14)
Buy
Level
56.53
ADX Line
Sell
Level
17.48
Williams %R
Neutral
Level
-20.8042
50-day SMA
Buy
Level
$26.62
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
318.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (17.3001)
Buy
CA Score
(Annual)
Level (0.3118)
Buy
Beneish M-Score
(Annual)
Level (-3.4987)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-2.5945)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
Stock Forecast FAQ
In the current month, ROIV has received 10 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ROIV average analyst price target in the past 3 months is $33.25.
-
Where Will Roivant Sciences Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Roivant Sciences Ltd. share price will rise to $33.25 per share over the next 12 months.
-
What Do Analysts Say About Roivant Sciences Ltd.?
Analysts are divided on their view about Roivant Sciences Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Roivant Sciences Ltd. is a Sell and believe this share price will drop from its current level to $22.00.
-
What Is Roivant Sciences Ltd.'s Price Target?
The price target for Roivant Sciences Ltd. over the next 1-year time period is forecast to be $33.25 according to 11 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ROIV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Roivant Sciences Ltd. is a Buy. 10 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ROIV?
You can purchase shares of Roivant Sciences Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Roivant Sciences Ltd. shares.
-
What Is The Roivant Sciences Ltd. Share Price Today?
Roivant Sciences Ltd. was last trading at $28.34 per share. This represents the most recent stock quote for Roivant Sciences Ltd.. Yesterday, Roivant Sciences Ltd. closed at $28.33 per share.
-
How To Buy Roivant Sciences Ltd. Stock Online?
In order to purchase Roivant Sciences Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ROIV Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ROIV
Sector
P/E ratio
1.91x
21.37x
PEG ratio
-0.03x
-0.01x
P/B ratio
4.75x
1.72x
Price / LTM sales
1,471.52x
1.44x
Growth Metrics
ROIV
Sector
Revenue growth
-77.83%
3.44%
Earnings growth
-262.8%
14.97%
Revenue (5-year growth)
-15.56%
6.27%
Earnings forecast
-$0.29
-$0.22
Profitability
ROIV
Sector
Profitability FY 2024
$20.8M
$2.4M
Return on invested capital
-19.48%
-33.43%
Return on assets
-18.95%
-29.45%
Return on equity
-19.87%
-40.29%
Earnings Date
Last Earnings Date
Feb
6
Next Earnings Date
May
28
Estimated Next Earnings Date
May
8
Balance Sheet
ROIV
Sector
Total cash
$4.5B
$25.6M
Short term investments
$2.2B
$22.7M
Total assets
$5.4B
$70.4M
Long term debt
$98.5M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
